|Bid||38.49 x 800|
|Ask||38.51 x 1200|
|Day's Range||38.44 - 38.61|
|52 Week Range||34.25 - 42.82|
|Beta (3Y Monthly)||-0.17|
|PE Ratio (TTM)||27.43|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.75|
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards .
Dr. Reddy’s Laboratories Ltd. confirms it had initiated a voluntary nationwide recall on October 1, 2019, of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine above levels established by the FDA.
We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Dr. Reddy's Laboratories Limited (NYSE:RDY) based on […]
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.